Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.

Pharmacogenomics - 1 Jan 2012

Lin Wei-Jiun, Chen James J

Abstract excerpt

AIM: A main goal of pharmacogenomics is to develop genomic signatures to predict patients' responses to a drug or therapy for treatment decisions. Identification of patients who would have no beneficial effect or have the risk of developing adverse effects from an unnecessary treatment could save enormous cost in the healthcare system and clinical trials. This article presents an approach for developing a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Computer Simulation
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genome, Human

Share to Models, Theoretical

Share to Sample Size

Source

Identifiers

PMID: 22188363
DOI: 10.2217/pgs.11.139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.PMID 22188363Read ↗

Biostatistic tools in pharmacogenomics--advances, challenges, potential.Semantic proximity Read ↗

Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working GroupSemantic proximity Read ↗

Selecting predictive biomarkers from genomic data.Semantic proximity Read ↗

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.Semantic proximity Read ↗

A hierarchical Bayes model for biomarker subset effects in clinical trialsSemantic proximity Read ↗

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.Semantic proximity Read ↗

Subpopulation-specific confidence designation for more informative biomedical classification.Semantic proximity Read ↗

A model-free ensemble method for class prediction with application to biomedical decision making.Semantic proximity Read ↗

Predose and Postdose Blood Gene Expression Profiles Identify the Individuals Susceptible to Acetaminophen-Induced Liver Injury in Rats.Semantic proximity Read ↗

A survival of the fittest strategy for the selection of genotypes by which drug responders and non-responders can be predicted in small groups.Semantic proximity Read ↗

Causal Phenotyping for Susceptibility to Cardiotoxicity from Antineoplastic Breast Cancer Medications.Semantic proximity Read ↗

Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.